|Articles|May 16, 2011

Nexera Medical's Surgical N95 Respirator Mask Features Embedded Antibacterial Performance

Sciessent LLC, creator of ionic silver-based antimicrobial brands Agion® and Agion Active, announces the U.S. release of the Nexera Medical SpectraShieldTM model 9500 Surgical Respirator Mask using Foss Manufacturings FOSSHIELD® fibers treated with Agion antimicrobial technology. The mask recently received FDA 510(k) and NIOSH clearance, making it the first surgical respirator mask with embedded antibacterial performance to achieve FDA clearance in the United States.

"Considered the model for the next generation respirator mask, the SpectraShield 9500 surgical respirator is equivalent to a N95 (NIOSH rating)," says Paul Sallarulo, CEO of Nexera Medical. "The SpectraShield 9500 surgical respirator mask begins to eliminate certain strains of bacteria immediately on contact. This is the first mask treated with both AgIon and FOSSHIELD technology to receive FDA and NIOSH approval, and were excited to introduce it to the U.S. market."

Sciessent's customized Agion branded antimicrobial solutions incorporate silver ions in a zeolite carrier. The silver ions exchange with other positive ions (often sodium) from the moisture in the environment, effecting a release of silver "on demand." Depending on the microorganism, Agion antimicrobial technology has been shown to initially reduce microbial populate ions within minutes to hours while maintaining optimal performance for years. FOSSHIELD® incorporates Agion antimicrobial technology in a fiber system to deliver effective protection from microbes for the life of the product. The fiber can be blended into almost any fabric from cotton to nylon without changing its characteristics.

"Independent testing in the United States and Europe has shown the masks ability to kill 99.99 percent of tested bacteria on the surface of the mask within an hour including Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes and Haemophilus influenza," says Paul Ford, CEO of Sciessent. "Sciessent has been steadily expanding our Agion technology into the medical device market, and were proud to partner on this innovative product with Foss and Nexera."


Related to this article

A brightly lit Hospital operating room, a surgical team wearing gowns and masks.  (Adobe Stock 1790696595 by Damian)
Turnover pressure can leave critical OR cleaning steps unfinished. Karen deKay, MSN, RN, EBP-C, CNOR, CIC, FAPIC, examines common gaps in environmental hygiene and how shared responsibilities, attention to disinfectant contact time, and ongoing education can help teams strengthen practices between cases.
Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Health care workers from the US speaking with other health care workers in DRC.  (Image credit: author with AI)
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.